{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:41:11Z","timestamp":1791830471359,"version":"4.3.4"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172814"],"award-info":[{"award-number":["82172814"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022A1515010267"],"award-info":[{"award-number":["2022A1515010267"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010096","name":"Southern Medical University","doi-asserted-by":"publisher","award":["2021CR003"],"award-info":[{"award-number":["2021CR003"]}],"id":[{"id":"10.13039\/501100010096","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["L246012"],"award-info":[{"award-number":["L246012"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009331","name":"Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support","doi-asserted-by":"publisher","award":["ZLRK202519"],"award-info":[{"award-number":["ZLRK202519"]}],"id":[{"id":"10.13039\/501100009331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020372","name":"Shanghai Junshi Biosciences","doi-asserted-by":"publisher","award":["2023ZD0501500"],"award-info":[{"award-number":["2023ZD0501500"]}],"id":[{"id":"10.13039\/100020372","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015956","name":"Special Project for Research and Development in Key areas of Guangdong Province","doi-asserted-by":"publisher","award":["2023B1111050009"],"award-info":[{"award-number":["2023B1111050009"]}],"id":[{"id":"10.13039\/501100015956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.eclinm.2025.103421","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T12:00:13Z","timestamp":1755000013000},"page":"103421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Efficacy and safety of neoadjuvant toripalimab plus chemotherapy in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma (NICE): a multicentre, single-arm, exploratory phase 2 study"],"prefix":"10.1016","volume":"87","author":[{"given":"Liying","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqiang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1966-6908","authenticated-orcid":false,"given":"Huayuan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junliang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfeng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2773-7048","authenticated-orcid":false,"given":"Guoxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2025.103421_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eclinm.2025.103421_bib2","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41586-022-04508-4","article-title":"Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer","volume":"603","author":"Shitara","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.eclinm.2025.103421_bib3","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2025.103421_bib4","article-title":"LBA3 Final analysis of the phase III KEYNOTE-585 study of pembrolizumab plus chemotherapy vs chemotherapy as perioperative therapy in locally-advanced gastric and gastroesophageal junction cancer","volume":"35","author":"Shitara","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2025.103421_bib5","volume":"42","author":"Janjigian","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103421_bib6","article-title":"Camrelizumab combined with FLOFOX as neoadjuvant therapy for resectable locally advanced gastric and gastroesophageal junction adenocarcinoma: updated results of efficacy and safety","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103421_bib7","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.4047","article-title":"A phase II study of perioperative mFOLFOX plus pembrolizumab combination in patients with potentially resectable adenocarcinoma of the esophageal, gastroesophageal junction (GEJ) and stomach","volume":"40","author":"Sun","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103421_bib8","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.4059","article-title":"Neoadjuvant atezolizumab plus docetaxel\/oxaliplatin\/capecitabine in non-metastatic gastric and gastroesophageal junction adenocarcinoma: the PANDA trial","volume":"40","author":"Verschoor","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103421_bib9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12943-018-0864-3","article-title":"Biomarkers for predicting efficacy of PD-1\/PD-L1 inhibitors","volume":"17","author":"Yi","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.eclinm.2025.103421_bib10","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.annonc.2020.03.299","article-title":"JSCO\u2014ESMO\u2014ASCO\u2014JSMO\u2014TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions","volume":"31","author":"Yoshino","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2025.103421_bib11","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/nm.4191","article-title":"Classification and characterization of microsatellite instability across 18 cancer types","volume":"22","author":"Hause","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2025.103421_bib12","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","article-title":"Assessment of pembrolizumab therapy for the treatment of microsatellite instability\u2013high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials","volume":"7","author":"Chao","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eclinm.2025.103421_bib13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1200\/JCO.22.00686","article-title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability\u2013high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study","volume":"41","author":"Andr\u00e9","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103421_bib14","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1200\/JCO.2023.41.4_suppl.358","article-title":"INFINITY: a multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC\/GEJAC)","volume":"41","author":"Pietrantonio","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103421_bib15","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1158\/2159-8290.CD-23-0857","article-title":"Early immune remodeling steers clinical response to first-line chemoimmunotherapy in advanced gastric cancer","volume":"14","author":"An","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eclinm.2025.103421_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2025.103421_bib17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","article-title":"Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ajani","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.eclinm.2025.103421_bib18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cac2.12516","article-title":"The Chinese society of clinical oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2023","volume":"44","author":"Wang","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.eclinm.2025.103421_bib19","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"Ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2025.103421_bib20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"10.1016\/j.eclinm.2025.103421_bib21","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/cncr.11660","article-title":"Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy: response of gastric carcinoma to chemotherapy","volume":"98","author":"Becker","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.eclinm.2025.103421_bib22","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1097\/SLA.0b013e318216f449","article-title":"Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases","volume":"253","author":"Becker","year":"2011","journal-title":"Ann Surg"},{"key":"10.1016\/j.eclinm.2025.103421_bib23","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaoncol.2016.6762","article-title":"Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the medical research council adjuvant gastric infusional chemotherapy (MAGIC) trial","volume":"3","author":"Smyth","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eclinm.2025.103421_bib24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1158\/2159-8290.CD-17-0787","article-title":"Genetic predictors of response to systemic therapy in esophagogastric cancer","volume":"8","author":"Janjigian","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eclinm.2025.103421_bib25","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/ijc.32030","article-title":"Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy","volume":"144","author":"Haag","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eclinm.2025.103421_bib26","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/jso.26669","article-title":"Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy","volume":"124","author":"Li","year":"2021","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.eclinm.2025.103421_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.08.1538","volume":"32","author":"Al-Batran","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2025.103421_bib28","doi-asserted-by":"crossref","first-page":"S589","DOI":"10.1016\/j.annonc.2022.07.145","article-title":"113P Pembrolizumab in microsatellite instability-high (MSI-H)\/mismatch repair deficient (dMMR) advanced solid tumors: an update of the phase II KEYNOTE-158 trial","volume":"33","author":"Maio","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2025.103421_bib29","doi-asserted-by":"crossref","first-page":"8616","DOI":"10.1245\/s10434-024-16030-0","article-title":"Clinical and pathologic response to neoadjuvant immunotherapy in DNA mismatch repair protein-deficient gastroesophageal cancers","volume":"31","author":"Shannon","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.eclinm.2025.103421_bib30","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s10120-022-01286-w","article-title":"A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer","volume":"25","author":"Hasegawa","year":"2022","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.eclinm.2025.103421_bib31","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2022.40.16_suppl.4003","volume":"40","author":"Al-Batran","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103421_bib32","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2093518","article-title":"PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer","volume":"11","author":"Liu","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.eclinm.2025.103421_bib33","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020106065","article-title":"5-Fluorouracil efficacy requires anti-tumor immunity triggered by cancer-cell-intrinsic STING","volume":"40","author":"Tian","year":"2021","journal-title":"EMBO J"},{"key":"10.1016\/j.eclinm.2025.103421_bib34","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/cam4.1878","article-title":"Oxaliplatin regulates myeloid-derived suppressor cell-mediated immunosuppression via downregulation of nuclear factor-\u03baB signaling","volume":"8","author":"Kim","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.eclinm.2025.103421_bib35","doi-asserted-by":"crossref","first-page":"733","DOI":"10.6061\/clinics\/2016(12)10","article-title":"Detection value of free cancer cells in peritoneal washing in gastric cancer: a systematic review and meta-analysis","volume":"71","author":"Tustumi","year":"2016","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.eclinm.2025.103421_bib36","article-title":"Efficacy and safety of conversion therapy by intraperitoneal and intravenous paclitaxel plus oral S-1 in gastric cancer patients with peritoneal metastasis: a prospective phase II study","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.eclinm.2025.103421_bib37","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1245\/s10434-010-1362-z","article-title":"7th edition of the AJCC cancer staging manual: Stomach","volume":"17","author":"Washington","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.eclinm.2025.103421_bib38","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1158\/1078-0432.CCR-23-1316","article-title":"Platinum-based chemotherapy attenuates the effector response of CD8 T cells to concomitant PD-1 blockade","volume":"30","author":"Mariniello","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eclinm.2025.103421_bib39","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","article-title":"Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations","volume":"24","author":"Butterfield","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.eclinm.2025.103421_bib40","first-page":"1546","article-title":"How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy","volume":"9","author":"Ma","year":"2019","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.eclinm.2025.103421_bib41","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant immunotherapy in locally advanced mismatch repair\u2013deficient colon cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103421_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103678","article-title":"Performances of preoperative CT scan to predict the pTN stage for MSI\/dMMR localized colon cancers","volume":"9","author":"Duval","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.eclinm.2025.103421_bib43","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair\u2013deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103421_bib44","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2025.103421_bib45","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","article-title":"Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade","volume":"6","author":"Chen","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eclinm.2025.103421_bib46","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1158\/1078-0432.CCR-17-2257","article-title":"CD103+ tumor-resident CD8+ T cells are associated with improved survival in immunotherapy-na\u00efve melanoma patients and expand significantly during anti-PD-1 treatment","volume":"24","author":"Edwards","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eclinm.2025.103421_bib47","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/s41591-022-02084-8","article-title":"Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1\/2 trial","volume":"28","author":"Kist De Ruijter","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2025.103421_bib48","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","article-title":"Targeting tumor-associated macrophages to synergize tumor immunotherapy","volume":"6","author":"Xiang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.eclinm.2025.103421_bib49","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.biomaterials.2019.03.011","article-title":"A microparticle platform for STING-targeted immunotherapy enhances natural killer cell- and CD8+ T cell-mediated anti-tumor immunity","volume":"205","author":"Watkins-Schulz","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.eclinm.2025.103421_bib50","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","article-title":"The biology of human natural killer-cell subsets","volume":"22","author":"Cooper","year":"2001","journal-title":"Trends Immunol"},{"key":"10.1016\/j.eclinm.2025.103421_bib51","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1182\/blood-2010-09-303057","article-title":"Dissecting CD56dim human NK cells","volume":"116","author":"Moretta","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2025.103421_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108377","article-title":"Immune-related adverse events of checkpoint inhibitors: insights into immunological dysregulation","volume":"213","author":"Yang","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1016\/j.eclinm.2025.103421_bib53","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1136\/thoraxjnl-2021-217260","article-title":"Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy","volume":"77","author":"Morelli","year":"2022","journal-title":"Thorax"},{"key":"10.1016\/j.eclinm.2025.103421_bib54","doi-asserted-by":"crossref","first-page":"S852","DOI":"10.1016\/j.annonc.2023.09.1426","article-title":"1513MO A phase II study of nivolumab plus low dose ipilimumab as first -line therapy in patients with advanced gastric or esophago-gastric junction MSI-H tumor: first results of the NO LIMIT study (WJOG13320G\/CA209-7W7)","volume":"34","author":"Muro","year":"2023","journal-title":"Ann Oncol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025003530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025003530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T20:21:55Z","timestamp":1772914915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025003530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":54,"alternative-id":["S2589537025003530"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103421","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of neoadjuvant toripalimab plus chemotherapy in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma (NICE): a multicentre, single-arm, exploratory phase 2 study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103421","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103421"}}